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Abstract
Background: Surgery is the primary treatment that can offer potential cure for gastric cancer, but is associated with significant risks.
Identifying optimal surgical approaches should be based on comparing outcomes from well designed trials. Currently, trials report different
outcomes, making synthesis of evidence difficult. To address this, the aim of this study was to develop a core outcome set (COS)—a stan-
dardized group of outcomes important to key international stakeholders—that should be reported by future trials in this field.
Methods: Stage 1 of the study involved identifying potentially important outcomes from previous trials and a series of patient
interviews. Stage 2 involved patients and healthcare professionals prioritizing outcomes using a multilanguage international Delphi
survey that informed an international consensus meeting at which the COS was finalized.
Results: Some 498 outcomes were identified from previously reported trials and patient interviews, and rationalized into 56 items
presented in the Delphi survey. A total of 952 patients, surgeons, and nurses enrolled in round 1 of the survey, and 662 (70 per cent) com-
pleted round 2. Following the consensus meeting, eight outcomes were included in the COS: disease-free survival, disease-specific survival,
surgery-related death, recurrence, completeness of tumour removal, overall quality of life, nutritional effects, and ‘serious’ adverse events.
Conclusion: A COS for surgical trials in gastric cancer has been developed with international patients and healthcare professionals.
This is a minimum set of outcomes that is recommended to be used in all future trials in this field to improve trial design and
synthesis of evidence.
Introduction
Gastric cancer is a significant global health burden which is asso-
ciated with poor survival1. Although the adoption of multimodal
therapy for the minority of patients who present with early-stage
disease has improved prognosis, surgery remains the only treat-
ment offering a potential cure2. Identifying the optimum surgical
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approach involves balancing the benefits of a radical oncological
resection against the risk and impact of associated complications
and physiological consequences. The ability to compare out-
comes from surgical trials in a clinically meaningful manner is
crucial to this process.
Homogeneity in the selection and reporting of key outcomes
between studies is necessary if useful synthesis of evidence is to
be achieved. However, outcome reporting in surgical trials for
gastric cancer is heterogeneous and not based on methodologi-
cally robust standards3. Even when similar outcomes are
reported, different definitions, measurement instruments, and
time points are used. Likewise, patient priorities and perspectives
tend to be overlooked when outcomes are selected by research-
ers. This potentially limits the subsequent relevance of aspects of
the research effort to the most important stakeholder group4. For
example, quality of life, an area identified as vitally important to
patients, is reported in less than 10 per cent of trials3.
To address this challenge, the GASTROS study (GAstric cancer
Surgery Trials Reported Outcomes Standardization) was under-
taken to develop a core outcome set (COS) for surgical trials in
gastric cancer5. A COS is ‘an agreed, standardized collection of
outcomes which should be measured and reported, as a mini-
mum, in all trials for a specific clinical area’6. Outcomes should
be relevant to key stakeholders, who should contribute to the
stages of COS development.
These challenges in outcome reporting are not limited to the
field of gastric cancer and affect virtually all clinical areas.
COMET (Core Outcome Measures in Effectiveness Trials; https://
www.comet-initiative.org) is an initiative that aims to promote
COS development7. Its registry database and up-to-date system-
atic reviews have comprehensively mapped COS projects across
all disciplines8–12. Although groups have developed COSs for dif-
ferent gastrointestinal cancers13–15, there has yet to be one devel-
oped for gastric cancer. The global incidence of gastric cancer
and differences in patient characteristics, management, and out-
comes, necessitated an international approach to this COS16,17.
An International Working Group (IWG) of collaborators was set
up to support this project, aided by a comprehensive network of
patient organizations, charities, and professional bodies across
six continents.
Methods
The GASTROS study conforms to standards established for the
development of COS as outlined by COS-STAD (Core Outcome
Set—STAndards for Development)18. This report uses the
COS-STAR (Core Outcome Set—STAndards for Reporting) stand-
ards to describe the development of a COS for surgical trials in
gastric cancer19. The checklist is provided in Table S1.
Scope
The scope, objectives, and methodological approaches of this
study have been described previously in detail5. In summary, the
COS developed in this study was aimed at all clinical effective-
ness trials examining therapeutic surgical trials for patients with
early-stage (potentially curable) gastric cancer. The GASTROS
study used existing best-practice approaches as developed by the
COMET Initiative, while adapting the methodological principles
to the challenges of an international consensus exercise. An over-
view of the study stages is shown in Fig. 1. This publication
describes stages 1 and 2.
Stakeholder participants and eligibility
The GASTROS study aimed to consider the views of key stake-
holders during the process, namely patients, surgeons, and on-
cology nurses. The guiding principle was to promote the patient
voice as they are the beneficiaries of trials in this field and have
all-important lived experience. Surgeons provide a clinical per-
spective and the experience of treating large volumes of patients.
Oncology nurses were invited to participate given their central
roles as caregivers, patient advocates, and core members of the
clinical team. Participation in the study was open to all interested
stakeholders who fulfilled the following criteria: surgeons who
had completed their training and routinely treat gastric cancer,
oncology nurses with a recognized proportion of their role in-
volved in the care and follow-up of patients with gastric cancer,
and patients who have undergone surgical resection for gastric
cancer with the intention of cure. Patients and healthcare profes-
sionals were identified through local, regional, and national clini-
cal and research networks. Support from patient groups,
charities, and professional societies was also key.
Stages of GASTROS study
Stage 1 (Fig. 1) identified outcomes that may be important to
stakeholders and stage 2 subsequently prioritized outcomes for
inclusion in the final COS (what to measure). In addition, the
GASTROS study aimed to collate the corresponding outcome
measurement instruments used in surgical trials and to deter-
mine the variability in measurement time points, for use in fu-
ture outcomes research (to determine how and when to measure)
in gastric cancer.
Stage 1: identifying outcomes
A systematic review of surgical trials for gastric cancer over two
decades was undertaken from which all reported outcomes were
extracted verbatim3. Patient-reported outcome measurement
instruments used in these trials were broken down into their
component parts to identify additional outcomes. To ensure that
patients’ perspectives were captured, a series of qualitative inter-
views exploring outcome prioritization was undertaken to iden-
tify potentially important outcomes not identified in the
systematic review4. A subsequent long list of potentially impor-
tant outcomes was compiled which underwent a process of ratio-
nalization, before being presented to the stakeholder groups for
prioritization in stage 2.
Stage 1: identifying potential outcomes
Systematic review
Patient interviews





















Fig. 1 Stages of the GASTROS study
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The rationalization process (Table S2) was initiated through
discussion within the Study Management Group (SMG) to merge
closely related items and map them against a taxonomy devel-
oped for COSs20. This process was assessed independently by an
external methodologist with extensive experience in COS devel-
opment. The resulting short list was presented to stakeholder
representatives (patients, surgeons, and oncology nurses) com-
prising the Study Advisory Group (SAG). The SAG was tasked
with ratifying the process so far, further merging of outcomes if
required, developing plain-language descriptions of the out-
comes, and identifying additional outcomes that they believed
had not yet been identified. Following this, the short list of out-
comes and corresponding plain-language descriptions were pre-
sented to a patient group as part of a cognitive debriefing
exercise to ensure understanding and comprehensibility.
Stage 2: prioritizing outcomes
To prioritize which items to include in the COS, patients, sur-
geons, and oncology nurses were invited to participate in an in-
ternational, multilanguage Delphi survey. The methodological
approach used to translate the surveys and recruit participants
has been described separately21. Although there is no formal
sample size requirement for Delphi surveys, recruitment was
facilitated with the support of a large network of professional
bodies, patient groups, and charities, to help ensure that a repre-
sentative spectrum of opinion was captured for each stakeholder
group.
Participants were invited to score outcomes in terms of impor-
tance on a Likert-type scale ranging from 1 to 9 (1–3,
not important; 4–6, important; 7–9, critically important) in a
two-round online Delphi survey. Participants were given the op-
portunity to add outcomes they considered were missing, for con-
sideration by participants in round 2. Suggested additional
outcomes were considered by the SMG and reviewed indepen-
dently by an external methodologist with experience of cancer-
related surgical COSs. The scores of each stakeholder group were
collated and summarized separately to ensure an equal voice
among stakeholder groups. Participants who had completed 50
per cent of the first survey were included in the round 1 analysis
and invited to participate in round 2. They were then presented
with group scores (presented as score distribution charts) for
each stakeholder group from round 1, and given the opportunity
to reflect on the opinions of others before deciding whether to
change their scores for each outcome in round 2. Those who
changed scores between rounds were able to provide a reason for
this18. After two rounds of voting, outcomes were categorized
according to predetermined criteria for inclusion in, or exclusion
from, the COS. Participants who had completed at least 50 per
cent of the survey in round 2 were included in the final analysis.
Any outcome scored as critically important (7–9) by more than
70 per cent and not important (1–3) by less than 15 per cent in all
three stakeholder groups was categorized for inclusion. Any out-
come scored as critically important (7–9) by less than 50 per cent
in all three stakeholder groups was categorized for exclusion.
These criteria were adapted from established COS methodology6.
Outcomes achieving any other combination of scores were cate-
gorized as not having reached consensus (no consensus) and pre-
sented for further discussion at a consensus meeting.
Survey participants were invited to attend a consensus meet-
ing in Manchester (UK) during March 2020. The aim of the meet-
ing was to review the results of the Delphi survey and consider
the outcomes for which no consensus was reached before finaliz-
ing the COS. Participants could take part by attending the
meeting venue in person, or through an online platform. The
meeting was undertaken in English and chaired by a clinical aca-
demic from the SMG with experience in COS development, and
with no clinical expertise in the management of gastric cancer.
Following discussion, stakeholders were asked to score out-
comes using the same criteria as was set out in the Delphi survey.
Similarly, scores from each stakeholder group were considered
separately to mitigate for imbalance in the numbers of each par-
ticipant type. Turning Point software (Turning Technologies,
Youngstown, OH, USA) was used to support voting at the venue
and online simultaneously. Participants were also asked to com-
plete an online voting form to mitigate against software malfunc-
tion. Outcomes reaching the original consensus criteria for
inclusion in the final COS were to be added to those included
from the Delphi survey.
Assessing bias
To assess the impact of attrition bias between survey rounds,
mean scores of participants completing both rounds of the
Delphi survey were compared against those of participants com-
pleting round 1 alone. Mean scores of those who took part in the
Delphi survey but did not attend the consensus meeting were
compared against the mean scores of those who attended to as-
sess the degree to which consensus meeting participants were
representative of those who participated in the survey. Both anal-
yses were undertaken using a t test to examine for statistically
significant differences at the 0.05 level. Furthermore, the charac-
teristics of stakeholders participating in both rounds were com-
pared with those who only completed round 1. A descriptive
analysis was undertaken, and the c2 test applied to examine for
statistically significant differences at the 0.05 level.
Patient and public involvement
A guiding principle of the GASTROS study was that patients’ voi-
ces should be represented at each stage of the project. Patient
representatives were integral with membership in the SAG and
support from international charities. The dissemination of
results from this study will be supported by a network of interna-
tional charities and patient support groups. The patient represen-
tatives opted to participate in the patient-focused study report of
results rather than the scientific dissemination.
Study registration and protocol
The GASTROS study was registered in the COMET database
(http://www.comet-initiative.org/studies/details/764?result¼
true) before commencement. The study protocol has been de-
scribed previously5.
Ethical approvals and portfolio adoption
Ethical approvals were required for the qualitative patient inter-
views and international Delphi surveys. The qualitative interview
study was given ethical approval by the National Research Ethics
Service North West—Cheshire (11/NW/0739) and governance
approvals by Central Manchester University Hospital National
Health Service (NHS) Foundation Trust. The Delphi survey was
given ethical approval by the North West—Greater Manchester
East Research Ethics Committee (18/NW/0347) and governance
approvals by Manchester University Hospitals NHS Foundation
Trust. Both the patient interviews and Delphi survey were
adopted on to the National Institute for Health Research (NIHR)
Clinical Research Network Portfolio (IDs 33312 and 38318).
Ethical approval for international participants was sought and
obtained locally by IWG collaborators.
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Results
The results for each stage of the study are summarized in
Fig. 2. The 498 outcomes identified from the systematic review,
patient-reported outcome measures, and patient interviews
were rationalized by the SMG into 58 items, which were pre-
sented to the SAG. The SAG merged chyle leak, nutritional
complications, respiratory function, surgical-site infection,
and time to ambulation into other existing outcomes. Bleeding,
anaesthetic complications, and destination on discharge were ex-
panded or added as separate outcomes, which meant that a total
of 56 items were presented to participants in the Delphi survey
(Table S3).
Delphi survey
A total of 1021 patients, surgeons, and oncology nurses registered
for the Delphi survey, of whom 952 (268 patients, 445 surgeons,
239 nurses) from 55 countries across six continents fulfilled the
criteria for inclusion in the round 1 analysis. Table 1 summarizes
the characteristics of those included in the analyses. Table S4
details the results of voting in both rounds. One additional out-
come (duration of stay in an intensive care ward) suggested by
participants in round 1 was presented in round 2 along with the
original 56 outcomes for rescoring (a total of 57 outcomes in
round 2). Although other outcomes were suggested by partici-
pants in round 1, these were deemed by the SMG and an external
reviewer as either direct duplication of outcomes already in-
cluded or not sufficiently unique that they warranted being pre-
sented separately (Table S5). Scores from 662 participants in
round 2 were included in the final analysis representing an attri-
tion rate of 30 per cent. Some 557 participants (84 per cent)
changed the score of least one answer from round 1, with 191 (29
per cent) participants changing a score to cross a boundary (for
example, from 1–3 to 4–6 or 7–9). A detailed analysis exploring
the reasons for changing scores has been reported previously18.
Consensus was reached to include 13 outcomes: disease-free
survival, disease-specific survival, surgery-related death, recur-
rence of cancer, completeness of tumour removal, overall quality
of life, nutritional effects, all-cause complications, intraoperative
complications, anaesthetic complications, anastomotic compli-
cations, multiple organ failure, and bleeding.
Thirteen outcomes were categorized for exclusion, and no
consensus was reached for 31 outcomes, which were subse-
quently discussed at the consensus meeting. An analysis explor-
ing the relationship between participant characteristics (such as
regional and demographic differences) and their impact on how
outcomes were scored is under review22.
There was no statistically significant difference between the
mean scores of participants completing both survey rounds and
those completing round 1 only (mean(s.d.) difference 0.17(0.1),
largest difference 0.4; P¼ 0.76).
Consensus meeting
Forty-three Delphi survey participants (7 patients, 29 surgeons, 7
nurses) attended the consensus meeting in person (18) or using
the online platform (25). Fourteen countries from four continents
(South America, North America, Europe, Asia) were represented.
A full breakdown of the regional origin of participants is de-
scribed in Appendix S1. The difference in mean scores between
consensus meeting participants and those completing round 2 of
the survey was statistically significant (mean(s.d.) difference
0.3(0.23), largest difference 1.16; P < 0.001).
In preparation for the consensus meeting, the SMG reviewed
and discussed the Delphi results. Of the 13 outcomes that
reached consensus to be included, six related to perioperative
complications. The SMG took the view that, as the outcome
all-cause complications was voted for inclusion, by extension, all
complications would need to be measured and reported by
researchers as a minimum. However, 14 complication-type out-
comes from the list of 57 did not reach consensus for inclusion
and a further two outcomes reached consensus for exclusion
from the COS. The SMG decided to present this seemingly contra-
dictory position at the consensus meeting for further discussion
and voting on a desired final position.
After an interactive debate, participants were asked to vote for
one of five propositions: all complications to be reported individu-
ally as a minimum; all ‘serious’ (without defining the term serious)
complications to be reported as a minimum; outcomes meeting
the criteria as core as set out by the GASTROS study to be included;
unsure; and other options. The result of this live vote was pre-
sented to participants, who were given an opportunity for further
discussion ahead of a final vote. The result of the second vote is
shown in Appendix S1. Votes were split between the first two
options, with the lack of a clear consensus mandating the need for
further work in this area. Consequently, all complication-type out-
comes were excluded from further discussion.
Non-complication-type outcomes for which there was no con-
sensus to include or exclude in the Delphi survey were then dis-
cussed. Results from the subsequent voting are presented in
Appendix S1. No further outcomes from this no-consensus group
were sufficiently prioritized for addition to the final COS. The
final COS is listed in Table 2. Participants agreed that future
work on complications, definitions, and when outcomes
should be reported should involve both patients and healthcare
professionals.
Protocol deviations
The original study protocol described a three-round Delphi
survey. Based on emerging evidence at that time23, several
COS developers have demonstrated that consensus can be
reached with a two-round survey, which was less resource- and
time-intensive. Consequently, the approach was altered and a
two-round Delphi adopted survey in the present study.
Discussion
The GASTROS study has developed the first COS for use in surgi-
cal trials for gastric cancer. This represents a significant step to-
wards addressing the current challenges related to outcome
reporting, synthesis of evidence, and research waste in this field.
Outcomes in the set were identified as critically important
through an inclusive international consensus process involving
patients and healthcare professionals. Further work is required
to develop the COS, in particular, finalizing definitions, seeking
consensus on how complications should be included, and identi-
fying appropriate outcome measurement instruments. In its pre-
sent form, the COS will guide trialists to which outcome domains
should be reported.
A COS can only achieve its stated aims if it is used by research-
ers. From the outset of the study, the SMG set out a clear strategy
to ensure buy-in by researchers and professional bodies. This
resulted in broad international support, and the development of
a network that enabled the recruitment of over 1000 participants
to the Delphi survey. These participants were well balanced in
terms of regional origins and personal or professional experience
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of gastric cancer. A strength of the study is that the methodology
used is based on consensus guidelines and has been transpar-
ently reported in detail at each stage5. Researchers can therefore
be reassured that the COS has been through a robust
development process and is a valid framework on which to base
their research, regardless of where it takes place.
A COS is a minimum set of critically important outcomes. It
does not limit trialists in their reporting of other outcomes of
Identifying outcomes
Outcome rationalization
Study advisory group review
Delphi survey round 1
Delphi survey round 2
Consensus meeting











1 additional outcome identified by participants in
round 1
57 outcomes presented in round 2 
13 outcomes achieved consensus for inclusion
in COS
13 outcomes achieved consensus for exclusion
from COS
No additional outcomes identified
8 outcomes included in COS
Complications grouped to be studied in future
work








416 outcomes and 38 patient-reported outcomes
20 patients interviewed
˜
70 outcomes from interviews




Fig. 2 Results from different stages of the GASTROS study
COS, core outcome set.
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interest. Furthermore, it should be noted that some grant-award-
ing bodies can make their own recommendations regarding
which outcomes should be reported as a minimum. An example
would be the recommendation to report overall survival, which
was not prioritized through the present consensus process24. As
such, it is recommended that researchers ensure that additional
outcomes selected in surgical trials for gastric cancer adequately
reflect the opinions of patients and clinicians in their region, as
well as taking into consideration other funding requirements.
The authors also recommend that further work is done to exam-
ine the international applicability of the COS.
The study was unable to achieve agreement with respect to
which complications should be included in the COS. The consen-
sus meeting could not decide whether all complications or only
‘serious’ complications should be reported as a minimum.
However, the overwhelming majority voted for one of these
options, which will be the focus of future work in this area. Other
surgical cancer-related COSs have differed in their recommenda-
tions for the reporting of complications. Some have included only
a small number of ‘serious’ or ‘core’ complication-related out-
comes15,25, whereas others have recommended the reporting of a
broader collection of complications26. Based on discussions from
the consensus meeting and the lack of agreement among other
COS developers, the current recommendation is that all ‘serious’
adverse events should be reported as a minimum until this area
is addressed further.
The term ‘serious’ was purposefully not defined at the consen-
sus meeting so as not to remove focus from the discussions.
Table 1 Demographic characteristics of participants included in analysis of round 1 and 2 scores





Patients (n 5 268) All 84 184
Age (years) 0.602
<60 38 (45) 77 (42)
60 46 (55) 107 (58)
Sex 0.345
M 52 (62) 101 (55)
F 32 (38) 83 (45)
Region 0.185
West 53 (63) 113 (61)
East 23 (27) 39 (21)
Other 8 (10) 32 (17)
Country income 0.792
HIC 53 (63) 113 (61)
LMIC 31 (37) 71 (39)
Time since surgery (years) 0.656
<1 15 (19) 30 (17)
1–3 34 (44) 68 (39)
>3 29 (37) 75 (43)
Surgical approach 0.850
Open 70 (83) 145 (78)
Minimally invasive 14 (17) 31 (22)
Type of gastrectomy 0.503
Total 40 (49) 78 (44)
Partial 42 (51) 98 (56)
Treatment modality 0.495
Surgery alone 28 (34) 69 (39)





West 33 (32) 174 (51)
East 53 (52) 109 (32)
Other 16 (16) 60 (17)
Country income 0.010
HIC 45 (44) 201 (57)
LMIC 57 (56) 142 (43)
Surgeon experience 0.450
<50 21 (29) 70 (23)
50–199 20 (27) 103 (34)
200 32 (44) 127 (42)
Nurses (n 5 239) All 104 135
Region 0.251
West 22 (21) 40 (30)
East 57 (56) 61 (45)
Other 25 (24) 34 (25)
Country income 0.064
HIC 24 (23) 46 (34)
LMIC 80 (77) 89 (66)
Nurse experience (years) 0.056
0–5 59 (57) 59 (45)
>5 44 (43) 73 (55)
Values in parentheses are percentages. HIC, high-income country; LMIC, low–middle-income country. *v2 test.
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Others have already attempted to define this; the Gastrectomy
Complications Consensus Group (GCCG) is a collaboration of
European surgeons who have prioritized a list of 27 clearly de-
fined complications which should be reported as a minimum in
research, audits, and registries27. They sought consensus through
a Delphi process, although their methodology differs from that of
the GASTROS study in that patients and non-European health-
care professionals did not participate. Currently, it is the only
substantial work available in this field addressing the reporting
of complications, and will undoubtedly contribute to, and shape,
future work in this field, which is being developed by the first
author.
Defining outcomes is an area that deserves further consider-
ation. The present approach was to use plain-language descrip-
tions to define outcomes presented in the Delphi survey and
consensus meetings. These were developed with the support of
the SAG and an independent patient group. This was necessary
to ensure that patients were engaged throughout the study and
made translations easier. It is acknowledged that these may not
be adequately detailed for use in trials, and more work is required
with researchers and patients to address this for the outcomes
included in the COS. Substantial work has already been under-
taken by the StEP-COMPAC (Standardized Endpoints in
Perioperative Medicine—Core Outcome Measures in Perioperative
and Anaesthetic Care) group to identify available definitions for
outcomes from several systematic reviews28–31. As with the
GCCG complication list, this process did not involve patients,
which was contrary to the recommendation made by the
GASTROS consensus meeting. Standardizing definitions for out-
comes included in this COS will form part of stage 3 of the
GASTROS study.
Identifying which outcomes to measure is the first step in
standardizing outcome reporting in this field. Although many
outcomes in the COS are event-type outcomes (such as complica-
tions, survival, and recurrence), some are composite outcomes
which require the use of an instrument to measure (for example,
quality of life and nutritional outcomes). There is currently
no standardized approach to measuring these outcomes32–34,
and selecting the best tools to measure them requires a robust
methodological approach similar to the one employed in this
study35,36. This will form the basis of future work.
There are limitations to the present study that require discus-
sion. It could be argued that, given the multimodal nature of
treatment for gastric cancer, the COS would be more relevant if it
incorporated all therapies including chemotherapy, radiotherapy,
and endotherapy. However, at the time that GASTROS was con-
ceived, there were 24 ongoing surgical trials planning to recruit
11 000 patients for whom non-surgical-related outcomes would
not be applicable or relevant. The timing of support from
Japanese and Korean collaborators meant that their participation
was through the English-language Delphi survey which likely
influenced the recruitment of patients from these countries.
Nonetheless, an exploratory analysis of the Delphi survey results
suggested that patients from Eastern countries did not prioritize
outcomes differently from their Western counterparts22. As dis-
cussed above, it is recommended that researchers work with
patients as partners to determine additional outcomes that are
important locally at the trial design phase.
Another consideration relates to the type of stakeholder
groups recruited to the study. It was agreed to limit participation
to patients, nurses, and surgeons as this represented a balance of
a broad spectrum of opinion but ensured that the study’s coordi-
nation and data analysis were manageable. It should be acknowl-
edged that other groups, such as caregivers, allied health
professionals, regulators, policymakers, and grant awarding bod-
ies, will also provide valuable opinion. Inclusion of these groups
will be considered in future stages of the GASTROS study and
when the COS is reviewed.
The consensus meeting was held in English, limiting partici-
pants to English speakers only. Although there was a broad spec-
trum of international representation from the surgeon group,
this was not mirrored by the patient or nurse stakeholders who
were primarily UK-based. That said, no further outcomes were
added following discussions, supporting the validity of the Delphi
process, which recruited widely in terms of regional origin and
other demographic characteristics across all three stakeholder
groups.
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Core outcome




Completeness of tumour removal
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consensus as a core outcome.†No consensus was reached with respect to
which outcomes should be reported as a minimum. ‘Serious’ adverse events
should be reported as a minimum while further work is undertaken in this
area.






/bjs/advance-article/doi/10.1093/bjs/znab192/6308782 by guest on 23 July 2021
H. Daneri; H. Olufemi Gbenga; H. Okabe; I. Kingsford Smith; I.
Olawale Lateef; I. Garosio; _I. Hatipoglu; I. Gockel; I. Negoi; I. S.-H.
Min; I. M. M. Mesquita; I. Diez del Val; J. H. F. Leemhuis; J. A.
Gossage; J. Weindelmayer; J. R. Izbicki; J. McKenzie Manson;
J. Kelly; J. H. M. B. Stoot; J. W. Haveman; J. D. Brown; J. Sultan;
J. Hassall; J. van Sandick; J. H. Saunders; J. K. Clarke;
J. Heisterkamp; J. I. Vargas R; J. M. Couselo Villanueva; J. Ingmire;
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Vries; N. Adami Andreollo; N. Köksal; N. Zanini; N. Kreuser; N.
Okkabaz; O. Damiana; O. Afuwape; O. Kayode Fasiku; O.
Comensoli; O. F. Koroye; P. Capener; P. Morgagni; P. M. Pernadas
Lages; P. M. Wilkerson; P. Turner; P. Dutton; P. Hayes; P. Vorwald;
P. Singh; Q. Gan; R. Kottayasamy Seenivasagam; R. Ayloor
Seshadri; R. Guevara Castro; R. Douglas; R. M. Koshy; R. Yıldırım;
R. J. E. Skipworth; R. A. Gould; R. C. Wetherill; R. Shaw; R. A.
Burley; R. Palatucci; R. Racalbuto; R. M. Correia Casaca; S. M.
Lagarde; S. Gana; S. Marietti; S. Qureshi; S. Morales-Conde; S.
Molfino; S. G. Barreto; S. Turkyilmaz; S. Turan-Trabzon; S. Frisch;
S. Castoldi; S. Belloni; S. Flisi; S. Galloway; S. R. Maria; S. Royston;
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